Charles River Laboratories International Aktie
WKN: 939391 / ISIN: US1598641074
|
06.11.2024 13:58:21
|
Charles River Laboratories Updates 2024 Guidance - Update
(RTTNews) - (Adds Outlook)
Charles River Laboratories International, Inc. (CRL) updated financial guidance for 2024. Revenue and non-GAAP earnings per share guidance have been narrowed and slightly raised from the midpoint of the previous ranges to principally reflect the third-quarter financial performance. Non-GAAP EPS is now projected in a range of $10.10 - $10.30, revised from prior guidance range of $9.90 - $10.20. Reported revenue is now expected to decline in the range of 3.0% - 2.0%, updated from prior guidance of decline in the range of 4.5% - 2.5%.
Q3 Results:
The company's bottom line came in at $68.68 million, or $1.33 per share. This compares with $87.39 million, or $1.69 per share, in last year's third quarter. Earnings per share on a non-GAAP basis was $2.59, a decrease of 4.8% from $2.72 per share, last year. Analysts on average had expected the company to earn $2.43 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items. For the quarter, revenue was $1.01 billion, a decrease of 1.6% from a year ago.
Shares of Charles River are up 15% in pre-market trade on Wednesday.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Charles River Laboratories International Inc.
|
06.10.26 |
Börse New York in Grün: S&P 500 zum Handelsstart auf grünem Terrain (finanzen.at) | |
|
05.10.26 |
Montagshandel in New York: S&P 500 letztendlich mit Gewinnen (finanzen.at) | |
|
05.10.26 |
S&P 500-Papier Charles River Laboratories International-Aktie: So viel Verlust wäre bei einem Investment in Charles River Laboratories International von vor 5 Jahren angefallen (finanzen.at) | |
|
28.09.26 |
S&P 500-Titel Charles River Laboratories International-Aktie: So viel Gewinn hätte ein Charles River Laboratories International-Investment von vor 3 Jahren eingefahren (finanzen.at) | |
|
24.09.26 |
Zurückhaltung in New York: S&P 500 verbucht zum Ende des Donnerstagshandels Abschläge (finanzen.at) | |
|
24.09.26 |
S&P 500-Handel aktuell: S&P 500 nachmittags leichter (finanzen.at) | |
|
24.09.26 |
Handel in New York: S&P 500 verbucht am Mittag Verluste (finanzen.at) | |
|
24.09.26 |
NYSE-Handel S&P 500 zum Start schwächer (finanzen.at) |
Analysen zu Charles River Laboratories International Inc.
Aktien in diesem Artikel
| Charles River Laboratories International Inc. | 258,30 | -3,66% |
|